Exploitation of Precision Medicine Trials Data: Examples of Long Responders From the SHIVA01 Trial.
Fiche publication
Date publication
janvier 2018
Journal
JCO precision oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr GAVOILLE Céline
Tous les auteurs :
Basse C, Morel C, Callens C, Pierron G, Servois V, Vincent-Salomon A, Jobard A, Alt M, Ricci F, Loirat D, Sablin MP, Bretagne M, Saint-Ghislain M, Hescot S, Gonçalves A, Tredan O, Dubot C, Gavoille C, Delord JP, Campone M, Isambert N, Belin L, Bieche I, Kamal M, Le Tourneau C
Lien Pubmed
Résumé
Precision medicine trials constitute a precious source of molecular data with prospective clinical annotations allowing the exploration of patients' subpopulations according to specific clinical or biological questions. Using the SHIVA01-the first randomized trial comparing molecularly targeted therapy on the basis of tumor molecular profiling versus conventional chemotherapy in metastatic cancer patients who failed standard of care therapy-annotated database, we report cases of patients treated in the trial with targeted therapy who experienced an objective response or prolonged disease stabilization in light of patients' molecular alterations.
Référence
JCO Precis Oncol. 2018 ;2: